Clinical Trials
29 trialsNCT03902184 2026-04-29
TELLOMAK
Innate Pharma
Phase 2 Completed
NCT06149247 2025-08-20
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Soligenix
Phase 2 Completed
NCT02953301 2024-08-30
RESMAIN
4SC AG
Phase 2 Completed
NCT05380635 2023-06-07
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Soligenix
Phase 2 Completed
NCT00071071 2023-05-18
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
Genmab
Phase 2 Completed
NCT00071084 2023-04-28
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
Genmab
Phase 2 Completed
NCT00002663 2023-02-13
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara Biotherapeutics
Phase 1/2 Completed
NCT02448381 2022-04-15
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Soligenix
Phase 3 Completed
NCT04955340 2022-02-18
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
4SC AG
Phase 1 Completed
NCT00425555 2021-08-20
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Novartis
Phase 2 Completed
NCT00406809 2021-08-02
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
AbbVie
Phase 1/2 Completed
NCT04702503 2021-01-11
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
Moleculin Biotech, Inc.
Phase 1 Completed
NCT01578499 2021-01-05
ALCANZA
Takeda
Phase 3 Completed
NCT02580552 2020-11-23
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
miRagen Therapeutics, Inc.
Phase 1 Completed
NCT02296164 2020-03-04
PROVe
Helsinn Therapeutics (U.S.), Inc
Completed
NCT00554827 2020-01-03
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01134341 2019-12-18
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01007448 2019-11-12
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Bausch Health Americas, Inc.
Phase 4 Completed
NCT00091559 2017-04-05
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00611208 2016-11-29
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Virogen Biotechnology Inc.
Phase 2 Completed
NCT00293488 2016-06-23
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
Progen Pharmaceuticals
Phase 1 Completed
NCT01748721 2016-01-08
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Morphotek
Phase 1 Completed
NCT00431912 2015-07-08
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
Valerio Therapeutics
Phase 2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00168064 2012-10-31
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
Yaupon Therapeutics
Phase 2 Completed
NCT00535470 2012-08-09
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
Yaupon Therapeutics
Phase 2 Completed
NCT00501735 2012-01-23
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
BioCryst Pharmaceuticals
Phase 2 Completed
NCT00050999 2008-03-05
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Eisai Inc.
Phase 4 Completed
NCT00051012 2008-03-05
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
Eisai Inc.
Phase 4 Completed